In the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims

- Claim 1. (Currently amended): A cellular proliferation assay for a compound acting through erbB-2 which comprises:
- i) <u>providing</u> a cell comprising erbB-2 and erbB-3 and which is responsive to ligand stimulated cell proliferation under conditions suitable for cell proliferation;
- ii) <u>providing</u> a first ligand which is a ligand for erbB-3 capable of inducing proliferation by the cell;
 - iii) mixingcontacting i) and ii) in the presence and absence of a compound; and
- iv) measuring determining whether the compound has any effect on reducing cell proliferation.
- Claim 2. (Original): A cellular proliferation assay according to claim 1 comprising the addition of a control wherein the compound is tested in parallel in the absence of ligand to detect non-specific cell toxicity.
- Claim 3. (Currently amended): A cellular proliferation assay according to claim 1 or 2 <u>further</u> comprising the addition of a second assay which is an assay for measuring whether the compound has activity through EGFR which comprises:
- i) <u>providing a second cell comprising erbB-2, erbB-3 and EGFR under conditions suitable for cell proliferation;</u>
- ii) a second ligand which is a ligand for EGFR capable of inducing proliferation by the <u>second</u> cell;
 - iii) mixingcontacting i) and ii) in the presence and absence of a compound; and
- iv) measuring determining whether the compound has any effect on reducing cell proliferation.
- Claim 4. (Currently amended) A cellular proliferation assay according to any preceding claims 1 or 2 wherein the cell endogenously expresses EGFR and/or erbB-2 and/or erbB-3.
- Claim 5. (Original): A cellular proliferation assay according to claim 4 wherein the cell endogenously expresses EGFR, erbB-2 and erbB-3.

Claim 6. (Currently amended): A cellular proliferation assay according to any preceding claim 1 wherein the first ligand is a heregulin.

Claim 7. (Original): A cellular proliferation assay according to claim 6 wherein the first ligand is heregulin β1.

Claim 8. (Currently amended): A cellular proliferation assay according to any one of claims 3-7claim 3 wherein the second ligand is EGF.

Claim 9. (Currently amended): A cellular proliferation assay according to <u>claims 1 or 3</u> any preceding claimwherein the cell is an immortalised normal epithelial H16N-2 cell.

Claim 10. (Currently amended): A cellular proliferation assay according to <u>claims 1 or 3</u> any one of claims 1-8 wherein the cell is a MCF-7 cell.